Cetuximab in the treatment of head and neck cancer: Preliminary results outside clinical trials

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 165-168

  Dequanter, Didier ^a   Shahla, Mohammad ^a   Paulus, Pascal ^a   Lothaire, Phillippe ^a  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

Author keywords

Clinical trials; Epidermal growth factor receptor antagonist; Head and neck cancer; Radiotherapy

Indexed keywords

CETUXIMAB; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; LOADING DRUG DOSE; MALE; RADIATION SICKNESS; RECURRENT CANCER; RETROSPECTIVE STUDY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

EID: 77955349677     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/cmr.s11085     Document Type: Article

References (14)

1. Saleh MN, Raisch K P, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14:451-463.
2. Rapidis AD, Vermorken JB, Bourhis J. Targeted therapies in head and neck cancer: past, present and future. Rev Recent Clin Trials. 2008;3:156-166.
3. Borockstein B, Lacouture M, Agulnik M. The role of inhibitors of epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008;7:696-706.
4. Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008;12:2635-2645.
5. Robert F, Ezekiel M P, Spencer SA. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
6. Bonner JA, Harrari P, Giralt J, Azarnia N, Shin DM, Cohen RB. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Eng J Med. 2006;354:567-578.
7. Bonner JA, Harari PM, Giralt J, Cohen B, Jones CH, Sur RJ, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
8. Bonner J, Harari PM, Giralt J. The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab. Int J Radiat Oncol Biol Phys. 2005;63:S73.
9. Lenz JH, Cutsem E V, Khambata-Ford S. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refratory to irinotecan, oxaliplatin, and fuoropyrimidines. J Clin Oncol. 2006;24:4914-4921.
10. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, Shu HK. Mutant epidermal growth factor receptor displays increased signalling through the phospahtdylinosotol-3 kibnase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004;23:4594-4602.
11. Budach W, Bölke E, Horney B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Eng J Med. 2007;357:514-515.
12. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N. Phase II multicenter study of the epidermal growth factor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577.
13. Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005;23:8646-8654.
14. Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006;11:1539-1552.